Hillary Millar Quinn, MS

Hillary has a diverse background in preclinical pharmacology, with over 20 years of experience in both large pharma and startup biotech settings. Her career has transitioned through Oncology, Immuno-Oncology, and Autoimmune disease areas, where she has experience developing small molecules, large molecules, oncolytic vaccines, and cell therapies. Hillary is familiar with pharmacology in every aspect of preclinical development, and thus understands the importance of matrixing, and the assay development that is necessary from compound screening through early development. Hillary’s work was key to the successful approval of SILVANT, SIMPONI, AKEEGA, BALVERSA, DARZALEX, and PROCRIT, and numerous discovery and clinical-stage programs at Johnson and Johnson. At Century Therapeutics, Hillary built the Pharmacology team and developed the preclinical evaluation strategy for multiple programs. As the pharmacology and toxicology lead, she brought CNTY-101, the first precision-engineered iPSC-derived cell therapy for lymphoma and autoimmune disease treatment, into the clinic.

  • Head of Preclinical Pharmacology, Century Therapeutics

    As one of the earliest employees of Century Therapeutics, built the In Vivo Pharmacology team and a Cell Biology and Ex Vivo/In Vitro analysis team; devised the preclinical strategy for testing multiple therapeutic candidates, including multiple precision-engineered iPSC-derived natural killer and gamma delta T cell therapies.

    Development of assays and models to interrogate oncology and autoimmune disease discovery candidates through candidate selection.

    Nonclinical lead including working closely with the Regulatory team, Manufacturing, and Early Development; participation in INTERACT and Pre-IND activities; liaising with CROs to develop and execute GLP safety studies (including site auditing); regulatory documentation including technical reports, IND modules, and Investigator Brochures.

  • Tumor Biology Team Lead, Janssen R&D and Janssen Pharmaceutica

    Leadership of domestic and international Preclinical Pharmacology teams to develop a range of therapeutic candidates in oncology. Pharmacology lead for colorectal cancer interception, heme malignancy, and solid tumor programs. Devised and executed on the preclinical strategy.

    Evaluation of small molecules and CAR-T therapies and a broad expertise in large molecules including monoclonal antibodies, bispecific antibodies/T cell engagers, and immune modulators.

    Development and characterization of orthotopic and metastatic hematological xenograft models, humanized models, transgenics, GEMMs, and carcinogen-induced colon adenoma and carcinoma models.

    IACUC and Ethical Committee representative for Oncology Research.